Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SEINRLF 56 10-Year RORE % is 4.33 as of Mar. 2026. GuruFocus rates INRLF with a GF Score™ of 56/100 and a GF Value™ of $2.95 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 615 Biotechnology companies, Valneva SE ranks better than 73.33% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Valneva SE's 10-Year RORE % for the quarter that ended in Mar. 2026 was 4.33%.
The industry rank for Valneva SE's 10-Year RORE % or its related term are showing as below:
INRLF's 10-Year RORE % is ranked better than 73.33% of 615
companies
in the Biotechnology industry
Industry Median: -6.41
vs INRLF: 4.33
Valneva SE (OTCPK:INRLF) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Valneva SE 10-Year RORE % Related Terms
Valneva SE 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Valneva SE's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INRLF vs VRTX, REGN, ALNY: 10-Year RORE % Comparison
For the Biotechnology subindustry, Valneva SE's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE 10-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Valneva SE's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Valneva SE (INRLF) has a 10-Year RORE % of 4.33 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #164 out of 615 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Valneva SE's 10-Year RORE % too high?
Valneva SE's current 10-Year RORE % is 4.33. Based on the distribution chart, Valneva SE ranks #164 out of 615 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Valneva SE has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's 10-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #164 out of 615 companies for 10-Year RORE %. This puts Valneva SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Valneva SE and its competitors. Valneva SE's current 10-Year RORE % is 4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.95, compared to a current price of $2.62 — trading 11.2% below its estimated fair value. The current 10-Year RORE % is 4.33. Valneva SE's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Valneva SE (INRLF), the current 10-Year RORE % is 4.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 11.2% below its estimated GF Value™ of $2.95.
GuruFocus considers Valneva SE to be Modestly Undervalued.
Key valuation signals for INRLF:
10-Year RORE %: 4.33
GF Value™: $2.95 vs. price of $2.62 (11.2% below fair value)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
56GF Score
Get the complete analysis for INRLF
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
